Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.

Gogola E, Duarte AA, de Ruiter JR, Wiegant WW, Schmid JA, de Bruijn R, James DI, Llobet SG, Vis DJ, Annunziato S, van den Broek B, Barazas M, Kersbergen A, van de Ven M, Tarsounas M, Ogilvie DJ, van Vugt M, Wessels LFA, Bartkova J, Gromova I, Andújar-Sánchez M, Bartek J, Lopes M, van Attikum H, Borst P, Jonkers J, Rottenberg S.

Cancer Cell. 2019 Jun 10;35(6):950-952. doi: 10.1016/j.ccell.2019.05.012. No abstract available.

2.

PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer.

Pantelidou C, Sonzogni O, De Oliveria Taveira M, Mehta AK, Kothari A, Wang D, Visal T, Li MK, Pinto J, Castrillon JA, Cheney EM, Bouwman P, Jonkers J, Rottenberg S, Guerriero JL, Wulf GM, Shapiro GI.

Cancer Discov. 2019 Jun;9(6):722-737. doi: 10.1158/2159-8290.CD-18-1218. Epub 2019 Apr 23.

PMID:
31015319
3.

Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response.

Francica P, Rottenberg S.

Genome Med. 2018 Dec 28;10(1):101. doi: 10.1186/s13073-018-0612-8. Review.

4.

The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity.

Becker JR, Cuella-Martin R, Barazas M, Liu R, Oliveira C, Oliver AW, Bilham K, Holt AB, Blackford AN, Heierhorst J, Jonkers J, Rottenberg S, Chapman JR.

Nat Commun. 2018 Dec 17;9(1):5406. doi: 10.1038/s41467-018-07855-x.

5.

Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.

Barazas M, Gasparini A, Huang Y, Küçükosmanoğlu A, Annunziato S, Bouwman P, Sol W, Kersbergen A, Proost N, de Korte-Grimmerink R, van de Ven M, Jonkers J, Borst GR, Rottenberg S.

Cancer Res. 2019 Feb 1;79(3):452-460. doi: 10.1158/0008-5472.CAN-18-2077. Epub 2018 Dec 10.

6.

Bacillus anthracis as a cause of bovine abortion - a necropsy case requiring special biosafety measures.

Dettwiler M, Mehinagic K, Gobeli Brawand S, Thomann A, Feyer S, Hüsser L, Theubet G, Gigandet J, Rottenberg S, Posthaus H.

Schweiz Arch Tierheilkd. 2018 Sep;160(9):547-552. doi: 10.17236/sat00176.

7.

53BP1 cooperation with the REV7-shieldin complex underpins DNA structure-specific NHEJ.

Ghezraoui H, Oliveira C, Becker JR, Bilham K, Moralli D, Anzilotti C, Fischer R, Deobagkar-Lele M, Sanchiz-Calvo M, Fueyo-Marcos E, Bonham S, Kessler BM, Rottenberg S, Cornall RJ, Green CM, Chapman JR.

Nature. 2018 Aug;560(7716):122-127. doi: 10.1038/s41586-018-0362-1. Epub 2018 Jul 25.

PMID:
30046110
8.

The shieldin complex mediates 53BP1-dependent DNA repair.

Noordermeer SM, Adam S, Setiaputra D, Barazas M, Pettitt SJ, Ling AK, Olivieri M, Álvarez-Quilón A, Moatti N, Zimmermann M, Annunziato S, Krastev DB, Song F, Brandsma I, Frankum J, Brough R, Sherker A, Landry S, Szilard RK, Munro MM, McEwan A, Goullet de Rugy T, Lin ZY, Hart T, Moffat J, Gingras AC, Martin A, van Attikum H, Jonkers J, Lord CJ, Rottenberg S, Durocher D.

Nature. 2018 Aug;560(7716):117-121. doi: 10.1038/s41586-018-0340-7. Epub 2018 Jul 18.

9.

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.

Gogola E, Duarte AA, de Ruiter JR, Wiegant WW, Schmid JA, de Bruijn R, James DI, Guerrero Llobet S, Vis DJ, Annunziato S, van den Broek B, Barazas M, Kersbergen A, van de Ven M, Tarsounas M, Ogilvie DJ, van Vugt M, Wessels LFA, Bartkova J, Gromova I, Andújar-Sánchez M, Bartek J, Lopes M, van Attikum H, Borst P, Jonkers J, Rottenberg S.

Cancer Cell. 2018 Jun 11;33(6):1078-1093.e12. doi: 10.1016/j.ccell.2018.05.008. Erratum in: Cancer Cell. 2019 Jun 10;35(6):950-952.

10.

The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells.

Barazas M, Annunziato S, Pettitt SJ, de Krijger I, Ghezraoui H, Roobol SJ, Lutz C, Frankum J, Song FF, Brough R, Evers B, Gogola E, Bhin J, van de Ven M, van Gent DC, Jacobs JJL, Chapman R, Lord CJ, Jonkers J, Rottenberg S.

Cell Rep. 2018 May 15;23(7):2107-2118. doi: 10.1016/j.celrep.2018.04.046.

11.

Haploid genetic screens identify genetic vulnerabilities to microtubule-targeting agents.

Gerhards NM, Blomen VA, Mutlu M, Nieuwenhuis J, Howald D, Guyader C, Jonkers J, Brummelkamp TR, Rottenberg S.

Mol Oncol. 2018 Jun;12(6):953-971. doi: 10.1002/1878-0261.12307. Epub 2018 May 1.

12.

Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas.

Meghani K, Fuchs W, Detappe A, Drané P, Gogola E, Rottenberg S, Jonkers J, Matulonis U, Swisher EM, Konstantinopoulos PA, Chowdhury D.

Cell Rep. 2018 Apr 3;23(1):100-111. doi: 10.1016/j.celrep.2018.03.038.

13.
14.

New tools for old drugs: Functional genetic screens to optimize current chemotherapy.

Gerhards NM, Rottenberg S.

Drug Resist Updat. 2018 Jan;36:30-46. doi: 10.1016/j.drup.2018.01.001. Epub 2018 Jan 12. Review.

15.

BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance.

Duarte AA, Gogola E, Sachs N, Barazas M, Annunziato S, R de Ruiter J, Velds A, Blatter S, Houthuijzen JM, van de Ven M, Clevers H, Borst P, Jonkers J, Rottenberg S.

Nat Methods. 2018 Feb;15(2):134-140. doi: 10.1038/nmeth.4535. Epub 2017 Dec 11.

PMID:
29256493
16.

A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity.

Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, Balgobind AV, Wind K, Gracanin A, Begthel H, Korving J, van Boxtel R, Duarte AA, Lelieveld D, van Hoeck A, Ernst RF, Blokzijl F, Nijman IJ, Hoogstraat M, van de Ven M, Egan DA, Zinzalla V, Moll J, Boj SF, Voest EE, Wessels L, van Diest PJ, Rottenberg S, Vries RGJ, Cuppen E, Clevers H.

Cell. 2018 Jan 11;172(1-2):373-386.e10. doi: 10.1016/j.cell.2017.11.010. Epub 2017 Dec 7.

17.

Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model.

Borst GR, Kumareswaran R, Yücel H, Telli S, Do T, McKee T, Zafarana G, Jonkers J, Verheij M, O'Connor MJ, Rottenberg S, Bristow RG.

Oncotarget. 2017 Sep 15;8(50):87638-87646. doi: 10.18632/oncotarget.20936. eCollection 2017 Oct 20.

18.

EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation.

Rondinelli B, Gogola E, Yücel H, Duarte AA, van de Ven M, van der Sluijs R, Konstantinopoulos PA, Jonkers J, Ceccaldi R, Rottenberg S, D'Andrea AD.

Nat Cell Biol. 2017 Nov;19(11):1371-1378. doi: 10.1038/ncb3626. Epub 2017 Oct 16.

PMID:
29035360
19.

Selected Alkylating Agents Can Overcome Drug Tolerance of G0-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice.

Pajic M, Blatter S, Guyader C, Gonggrijp M, Kersbergen A, Küçükosmanoğlu A, Sol W, Drost R, Jonkers J, Borst P, Rottenberg S.

Clin Cancer Res. 2017 Nov 15;23(22):7020-7033. doi: 10.1158/1078-0432.CCR-17-1279. Epub 2017 Aug 18.

20.

Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells.

Schoonen PM, Talens F, Stok C, Gogola E, Heijink AM, Bouwman P, Foijer F, Tarsounas M, Blatter S, Jonkers J, Rottenberg S, van Vugt MATM.

Nat Commun. 2017 Jul 17;8:15981. doi: 10.1038/ncomms15981.

21.

Genetic Dissection of Cancer Development, Therapy Response, and Resistance in Mouse Models of Breast Cancer.

Annunziato S, Barazas M, Rottenberg S, Jonkers J.

Cold Spring Harb Symp Quant Biol. 2016;81:141-150. doi: 10.1101/sqb.2016.81.030924. Epub 2016 Nov 4. Review.

22.

Erratum: Replication fork stability confers chemoresistance in BRCA-deficient cells.

Chaudhuri AR, Callen E, Ding X, Gogola E, Duarte AA, Lee JE, Wong N, Lafarga V, Calvo JA, Panzarino NJ, John S, Day A, Crespo AV, Shen B, Starnes LM, de Ruiter JR, Daniel JA, Konstantinopoulos PA, Cortez D, Cantor SB, Fernandez-Capetillo O, Ge K, Jonkers J, Rottenberg S, Sharan SK, Nussenzweig A.

Nature. 2016 Nov 17;539(7629):456. doi: 10.1038/nature19826. Epub 2016 Sep 28. No abstract available.

PMID:
27680696
23.

Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer.

Warmoes M, Lam SW, van der Groep P, Jaspers JE, Smolders YH, de Boer L, Pham TV, Piersma SR, Rottenberg S, Boven E, Jonkers J, van Diest PJ, Jimenez CR.

Oncotarget. 2016 Sep 27;7(39):63537-63548. doi: 10.18632/oncotarget.11535.

24.

The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.

Oplustil O'Connor L, Rulten SL, Cranston AN, Odedra R, Brown H, Jaspers JE, Jones L, Knights C, Evers B, Ting A, Bradbury RH, Pajic M, Rottenberg S, Jonkers J, Rudge D, Martin NM, Caldecott KW, Lau A, O'Connor MJ.

Cancer Res. 2016 Oct 15;76(20):6084-6094. Epub 2016 Aug 22.

25.

BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.

Drost R, Dhillon KK, van der Gulden H, van der Heijden I, Brandsma I, Cruz C, Chondronasiou D, Castroviejo-Bermejo M, Boon U, Schut E, van der Burg E, Wientjens E, Pieterse M, Klijn C, Klarenbeek S, Loayza-Puch F, Elkon R, van Deemter L, Rottenberg S, van de Ven M, Dekkers DH, Demmers JA, van Gent DC, Agami R, Balmaña J, Serra V, Taniguchi T, Bouwman P, Jonkers J.

J Clin Invest. 2016 Aug 1;126(8):2903-18. doi: 10.1172/JCI70196. Epub 2016 Jul 25.

26.

Replication fork stability confers chemoresistance in BRCA-deficient cells.

Ray Chaudhuri A, Callen E, Ding X, Gogola E, Duarte AA, Lee JE, Wong N, Lafarga V, Calvo JA, Panzarino NJ, John S, Day A, Crespo AV, Shen B, Starnes LM, de Ruiter JR, Daniel JA, Konstantinopoulos PA, Cortez D, Cantor SB, Fernandez-Capetillo O, Ge K, Jonkers J, Rottenberg S, Sharan SK, Nussenzweig A.

Nature. 2016 Jul 21;535(7612):382-7. doi: 10.1038/nature18325. Erratum in: Nature. 2016 Nov 17;539(7629):456.

27.

HELB Is a Feedback Inhibitor of DNA End Resection.

Tkáč J, Xu G, Adhikary H, Young JTF, Gallo D, Escribano-Díaz C, Krietsch J, Orthwein A, Munro M, Sol W, Al-Hakim A, Lin ZY, Jonkers J, Borst P, Brown GW, Gingras AC, Rottenberg S, Masson JY, Durocher D.

Mol Cell. 2016 Feb 4;61(3):405-418. doi: 10.1016/j.molcel.2015.12.013. Epub 2016 Jan 7.

28.

Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer.

Yu H, Hendrikx JJ, Rottenberg S, Schellens JH, Beijnen JH, Huitema AD.

AAPS J. 2016 Mar;18(2):362-71. doi: 10.1208/s12248-015-9838-1. Epub 2015 Nov 24.

29.

Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs.

Planells-Cases R, Lutter D, Guyader C, Gerhards NM, Ullrich F, Elger DA, Kucukosmanoglu A, Xu G, Voss FK, Reincke SM, Stauber T, Blomen VA, Vis DJ, Wessels LF, Brummelkamp TR, Borst P, Rottenberg S, Jentsch TJ.

EMBO J. 2015 Dec 14;34(24):2993-3008. doi: 10.15252/embj.201592409. Epub 2015 Nov 3.

30.

Minimal residual disease in cancer therapy--Small things make all the difference.

Blatter S, Rottenberg S.

Drug Resist Updat. 2015 Jul-Aug;21-22:1-10. doi: 10.1016/j.drup.2015.08.003. Epub 2015 Aug 14. Review.

PMID:
26307504
31.

Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model.

Hendrikx JJ, Lagas JS, Song JY, Rosing H, Schellens JH, Beijnen JH, Rottenberg S, Schinkel AH.

Int J Cancer. 2016 Feb 1;138(3):758-69. doi: 10.1002/ijc.29812. Epub 2015 Sep 21.

32.

Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.

Henneman L, van Miltenburg MH, Michalak EM, Braumuller TM, Jaspers JE, Drenth AP, de Korte-Grimmerink R, Gogola E, Szuhai K, Schlicker A, Bin Ali R, Pritchard C, Huijbers IJ, Berns A, Rottenberg S, Jonkers J.

Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8409-14. doi: 10.1073/pnas.1500223112. Epub 2015 Jun 22.

33.

Increased levels of choline metabolites are an early marker of docetaxel treatment response in BRCA1-mutated mouse mammary tumors: an assessment by ex vivo proton magnetic resonance spectroscopy.

van Asten JJ, Vettukattil R, Buckle T, Rottenberg S, van Leeuwen F, Bathen TF, Heerschap A.

J Transl Med. 2015 Apr 9;13:114. doi: 10.1186/s12967-015-0458-4.

34.

CopywriteR: DNA copy number detection from off-target sequence data.

Kuilman T, Velds A, Kemper K, Ranzani M, Bombardelli L, Hoogstraat M, Nevedomskaya E, Xu G, de Ruiter J, Lolkema MP, Ylstra B, Jonkers J, Rottenberg S, Wessels LF, Adams DJ, Peeper DS, Krijgsman O.

Genome Biol. 2015 Feb 27;16:49. doi: 10.1186/s13059-015-0617-1.

35.

REV7 counteracts DNA double-strand break resection and affects PARP inhibition.

Xu G, Chapman JR, Brandsma I, Yuan J, Mistrik M, Bouwman P, Bartkova J, Gogola E, Warmerdam D, Barazas M, Jaspers JE, Watanabe K, Pieterse M, Kersbergen A, Sol W, Celie PHN, Schouten PC, van den Broek B, Salman A, Nieuwland M, de Rink I, de Ronde J, Jalink K, Boulton SJ, Chen J, van Gent DC, Bartek J, Jonkers J, Borst P, Rottenberg S.

Nature. 2015 May 28;521(7553):541-544. doi: 10.1038/nature14328. Epub 2015 Mar 23.

36.

Real-Time In Vivo Characterization of Primary Liver Tumors With Diffuse Optical Spectroscopy During Percutaneous Needle Interventions: Feasibility Study in Woodchucks.

Nachabé R, Hendriks BH, Schierling R, Hales J, Racadio JM, Rottenberg S, Ruers TJ, Babic D, Racadio JM.

Invest Radiol. 2015 Jul;50(7):443-8. doi: 10.1097/RLI.0000000000000149.

37.

BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance.

Jaspers JE, Sol W, Kersbergen A, Schlicker A, Guyader C, Xu G, Wessels L, Borst P, Jonkers J, Rottenberg S.

Cancer Res. 2015 Feb 15;75(4):732-41. doi: 10.1158/0008-5472.CAN-14-0839. Epub 2014 Dec 15.

38.

Monitoring of tumor response to Cisplatin using optical spectroscopy.

Spliethoff JW, Evers DJ, Jaspers JE, Hendriks BH, Rottenberg S, Ruers TJ.

Transl Oncol. 2014 Apr;7(2):230-9. doi: 10.1016/j.tranon.2014.02.009. Epub 2014 Mar 4.

39.

Identifying subgroup markers in heterogeneous populations.

de Ronde JJ, Rigaill G, Rottenberg S, Rodenhuis S, Wessels LF.

Nucleic Acids Res. 2013 Nov;41(21):e200. doi: 10.1093/nar/gkt845. Epub 2013 Sep 22.

40.

Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin.

Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, Nieuwland M, Ovaa H, Rottenberg S, van Tellingen O, Janssen J, Huijgens P, Zwart W, Neefjes J.

Nat Commun. 2013;4:1908. doi: 10.1038/ncomms2921.

41.

Proteomics of genetically engineered mouse mammary tumors identifies fatty acid metabolism members as potential predictive markers for cisplatin resistance.

Warmoes M, Jaspers JE, Xu G, Sampadi BK, Pham TV, Knol JC, Piersma SR, Boven E, Jonkers J, Rottenberg S, Jimenez CR.

Mol Cell Proteomics. 2013 May;12(5):1319-34. doi: 10.1074/mcp.M112.024182. Epub 2013 Feb 8.

42.

Intra-operative ex vivo photoacoustic nodal staging in a rat model using a clinical superparamagnetic iron oxide nanoparticle dispersion.

Grootendorst DJ, Fratila RM, Visscher M, Haken BT, van Wezel RJ, Rottenberg S, Steenbergen W, Manohar S, Ruers TJ.

J Biophotonics. 2013 Jun;6(6-7):493-504. doi: 10.1002/jbio.201200204. Epub 2013 Jan 22.

PMID:
23341267
43.

MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression.

Rottenberg S, Jonkers J.

Breast Cancer Res. 2012 Nov 5;14(6):324. doi: 10.1186/bcr3327.

44.

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R, Wientjens E, Ji J, Aly A, Doroshow JH, Cranston A, Martin NM, Lau A, O'Connor MJ, Ganesan S, Borst P, Jonkers J, Rottenberg S.

Cancer Discov. 2013 Jan;3(1):68-81. doi: 10.1158/2159-8290.CD-12-0049. Epub 2012 Oct 25.

45.

EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.

Zander SA, Sol W, Greenberger L, Zhang Y, van Tellingen O, Jonkers J, Borst P, Rottenberg S.

PLoS One. 2012;7(9):e45248. doi: 10.1371/journal.pone.0045248. Epub 2012 Sep 17.

46.

Lack of ABCG2 shortens latency of BRCA1-deficient mammary tumors and this is not affected by genistein or resveratrol.

Zander SA, Kersbergen A, Sol W, Gonggrijp M, van de Wetering K, Jonkers J, Borst P, Rottenberg S.

Cancer Prev Res (Phila). 2012 Aug;5(8):1053-60. doi: 10.1158/1940-6207.CAPR-12-0050. Epub 2012 Jul 5.

47.

Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.

Rottenberg S, Vollebergh MA, de Hoon B, de Ronde J, Schouten PC, Kersbergen A, Zander SA, Pajic M, Jaspers JE, Jonkers M, Lodén M, Sol W, van der Burg E, Wesseling J, Gillet JP, Gottesman MM, Gribnau J, Wessels L, Linn SC, Jonkers J, Borst P.

Cancer Res. 2012 May 1;72(9):2350-61. doi: 10.1158/0008-5472.CAN-11-4201. Epub 2012 Mar 6.

48.

Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer.

Warmoes M, Jaspers JE, Pham TV, Piersma SR, Oudgenoeg G, Massink MP, Waisfisz Q, Rottenberg S, Boven E, Jonkers J, Jimenez CR.

Mol Cell Proteomics. 2012 Jul;11(7):M111.013334. doi: 10.1074/mcp.M111.013334. Epub 2012 Feb 24.

49.

Drug resistance in the mouse cancer clinic.

Rottenberg S, Borst P.

Drug Resist Updat. 2012 Feb-Apr;15(1-2):81-9. doi: 10.1016/j.drup.2012.01.001. Epub 2012 Feb 14. Review.

50.

BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.

Drost R, Bouwman P, Rottenberg S, Boon U, Schut E, Klarenbeek S, Klijn C, van der Heijden I, van der Gulden H, Wientjens E, Pieterse M, Catteau A, Green P, Solomon E, Morris JR, Jonkers J.

Cancer Cell. 2011 Dec 13;20(6):797-809. doi: 10.1016/j.ccr.2011.11.014.

Supplemental Content

Loading ...
Support Center